aglepristone profile

aglepristone: Alizine is tradename [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	14153279
CHEMBL ID	2103998
CHEBI ID	177608
SCHEMBL ID	2108967
MeSH ID	M0377411

Synonym
CHEBI:177608
(8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-[(z)-prop-1-enyl]-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
aglepristone (inn)
alizine (tn)
124478-60-0
D07096
aglepristone
aglepristone [inn]
unii-0ut4jle1cm
0ut4jle1cm ,
11beta-(p-(dimethylamino)phenyl)-17beta-hydroxy-17-((z)-propenyl)estra-4,9-dien-3-one
aglepristone [mi]
11.beta.-(p-(dimethylamino)phenyl)-17.beta.-hydroxy-17-((z)-propenyl)estra-4,9-dien-3-one
aglepristone [mart.]
CHEMBL2103998
alizine
AKOS025311442
SCHEMBL2108967
4-methyl-2-pyridin-2-yl-1,3-thiazole-5-carboxylicacid
DTXSID001016632

Research Excerpts

Overview

Aglepristone (RU534) is an antiprogestin used for pregnancy termination, parturition induction and conservative pyometra treatment in bitches. Agle Pristone is a safe abortifacient in cats, dogs and rabbits.

Excerpt	Reference	Relevance
"Aglepristone is a safe abortifacient in cats, dogs and rabbits. "	( Clinical, ultrasonography and haematology of aglepristone-induced mid-gestation pregnancy terminations in rabbits. Özalp, GR; Özocak-Batmaz, E; Temizel, EM, 2013)	2.09
"Aglepristone (RU534) is an antiprogestin used for pregnancy termination, parturition induction and conservative pyometra treatment in bitches. "	( Lack of in vitro effect of aglepristone on IFN-γ and IL-4 production by resting and mitogen-activated T cells of luteal bitches. Borkowska, J; Jurka, P; Szulc-Dąbrowska, L; Winnicka, A, 2013)	2.13
"Aglepristone (RU 46534) is a competitive progesterone antagonist that is indicated for the treatment of various progesterone-dependent physiological or pathologic conditions. "	( Aglepristone: A review on its clinical use in animals. Fiéni, F; Gogny, A, 2016)	3.32

Treatment

Aglepristone treatment in mid-gestation had no effect on IGF1 and IGF1R mRNA levels. Treatment caused substantial downregulation of luteal LEP expression by 72 h post-treatment (P ≤ 0.01)

Excerpt	Reference	Relevance
"Aglepristone treatment in mid-gestation had no effect on IGF1 and IGF1R mRNA levels."	( Expression of insulin-like growth factor 1 and its receptor in preovulatory follicles and in the corpus luteum in the bitch. Balogh, O; Boos, A; Kowalewski, MP; Müller, L; Reichler, IM, 2018)	1.2
"Aglepristone treatment induced embryonic fluid resorptions without foetal death in mid-gestation terminations."	( Clinical, ultrasonography and haematology of aglepristone-induced mid-gestation pregnancy terminations in rabbits. Özalp, GR; Özocak-Batmaz, E; Temizel, EM, 2013)	1.37
"Aglepristone treatment resulted in a decrease of Lep mRNA levels from 24 to 72 h in the Ut without concomitant changes in the Ut/Pl or in LepR levels."	( Leptin in the canine uterus and placenta: possible implications in pregnancy. Balogh, O; Boos, A; Gram, A; Kowalewski, MP; Reichler, IM; Staub, LP, 2015)	1.14
"Aglepristone treatment increased DFP of animals bearing PR+ tumours with size smaller than 3 cm, complex and mixed tumours, with histologic grades I and II, and with PI ≤ 10%."	( Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor-positive canine mammary carcinomas. De Andres, J; Domingo, V; García-Macías, J; Guil-Luna, S; Martín de Las Mulas, J; Millán, Y; Rollón, E; Sánchez-Céspedes, R, 2017)	1.46
"Aglepristone treatments are possibly not affecting further fertilities before implantation."	( Effects of the progesterone receptor antagonist aglepristone on implantation administered on days 6 and 7 after mating in rabbits. Calişkan, C; Ozalp, GR; Seyrek-Intaş, K; Wehrend, A, 2010)	1.34
"Aglepristone treatment had no significant effect compared to MPA alone."	( Effects of the anti-progestin aglepristone on the uterine tissue of cats administered medroxyprogesterone acetate. Chatdarong, K; Muphung, W; Rungsipipat, A, 2009)	1.36
"Aglepristone treatment did not affect fertility in following cycles."	( Induction of abortion with aglepristone in cats on day 45 and 46 after mating. Bostedt, H; Dimitrov, M; Georgiev, P; Goericke-Pesch, S; Petkov, P; Stojanthev, K; Tsoneva, V; Wehrend, A, 2010)	1.38
"Aglepristone treatment caused substantial downregulation of luteal LEP expression by 72 h post-treatment (P ≤ 0.01)."	( Leptin and leptin receptor gene expression in the canine corpus luteum during diestrus, pregnancy and after aglepristone-induced luteolysis. Balogh, O; Kowalewski, MP; Reichler, IM, 2012)	1.31
"Treatment with Aglepristone led to downregulation of PPARγ in either compartment, implying the functional interrelationship with progesterone receptor."	( Expression and functional implications of peroxisome proliferator-activated receptor gamma (PPARγ) in canine reproductive tissues during normal pregnancy and parturition and at antiprogestin induced abortion. Aslan, S; Boos, A; Hoffmann, B; Kowalewski, MP; Meyer, A, 2011)	0.71
"Treatment with aglepristone did not modify plasma concentrations of progesterone, prostaglandin, oxytocin or cortisol within 24 h after its administration, but it induced, in mid-pregnancy (group 2) a discharge of prolactin within 12 h after its administration."	( Hormonal variation in bitches after early or mid-pregnancy termination with aglepristone (RU534). Bernard, F; Bruyas, JF; Fieni, F; Marnet, PG; Martal, J; Riou, M; Siliart, B; Tainturier, D, 2001)	0.88

Compound-Compound Interactions

Excerpt	Reference	Relevance
" For this purpose we compared the effects of aglepristone (AGL) alone and in combination with cloprostenol (CLO) on serum concentrations of progesterone (P4), estradiol (E2) and relaxin (RLN) measured at short-term intervals during the abortion period in bitches."	( The effects of aglepristone alone and in combination with cloprostenol on hormonal values during termination of mid-term pregnancy in bitches. Ağaoğlu, AR; Aslan, S; Ay, SS; Bal, Y; Einspanier, A; Emre, B; Gültiken, N; Gürcan, IS; Kaya, D; Küçükaslan, I; Schäfer-Somi, S, 2014)	1.02

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Class	Description
oxo steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (39.02)	29.6817
2010's	46 (56.10)	24.3611
2020's	4 (4.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	20 (23.81%)	5.53%
Reviews	2 (2.38%)	6.00%
Case Studies	5 (5.95%)	4.05%
Observational	0 (0.00%)	0.25%
Other	57 (67.86%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.08	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	2.05	1	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	2.05	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
medroxyprogesterone acetate [no description available]	9.67	3	2	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
chlormadinone acetate Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL).	2.01	1	0	corticosteroid hormone
sulfadoxine Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.. sulfadoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.	2.05	1	0	pyrimidines; sulfonamide	antibacterial drug; antimalarial
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	4.9	4	2	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
proligestone proligestone: a synthetic progestational steroid; used to suppress ESTRUS	2.01	1	0
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	5.24	6	2	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
estrone sulfate estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd	2.05	1	0	17-oxo steroid; steroid sulfate	human metabolite; mouse metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.08	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	5.03	9	1	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
misoprostol Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.	3.87	2	1
15-keto-13,14-dihydroprostaglandin f2alpha 15-keto-13,14-dihydroprostaglandin F2alpha: main metabolite of PGF2alpha in plasma after allergen provoked asthma; RN given refers to (5Z,9alpha,11alpha)-isomer; structure. 13,14-dihydro-15-keto-PGF2alpha : A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F2alpha.	2.93	4	0	ketone; prostaglandins Falpha	metabolite
cloprostenol Cloprostenol: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.	6.12	8	4	prostanoid
ergoline Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.. ergoline : An indole alkaloid whose structural skeleton is found in many naturally occurring and synthetic ergolines which are known to bind to neurotransmitter receptors, such as dopamine, noradrenaline and serotonin receptors and function as unselective agonists or antagonists at these receptors.	4.9	4	2	diamine; ergoline alkaloid; indole alkaloid fundamental parent; indole alkaloid; organic heterotetracyclic compound
amoxicillin-potassium clavulanate combination Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.	3.4	1	1
contraceptives, postcoital Contraceptives, Postcoital: Contraceptive substances to be used after COITUS. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; ANTIMETABOLITES; ALKALOIDS, and PROSTAGLANDINS.	2.05	1	0
alfaprostol alfaprostol: RN given refers to 1R-(1alpha(Z),2beta(S*), 3alpha,5alpha)-isomer; structure in first source	2.46	2	0
delmadinone [no description available]	2.01	1	0
leptin Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.	7.49	2	0

Condition	Relationship Strength	Studies	Trials
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	9.73	54	10
Canine Diseases [description not available]	7.69	16	4
Fibroid [description not available]	2.25	1	0
Cancer of Ovary [description not available]	2.25	1	0
Gestational Luteoma [description not available]	2.25	1	0
Cancer of the Vagina [description not available]	2.5	2	0
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	2.25	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.25	1	0
Vaginal Neoplasms Tumors or cancer of the VAGINA.	2.5	2	0
Abortion, Veterinary Premature expulsion of the FETUS in animals.	8.09	20	5
Birth Weight The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.	2.47	2	0
Edema-Proteinuria-Hypertension Gestosis [description not available]	2.17	1	0
Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.	2.17	1	0
Recrudescence [description not available]	2.75	3	0
Pyometra An accumulation of PUS in the uterine cavity (UTERUS). Pyometra generally indicates the presence of infections.	4.98	8	0
Atypical Endometrial Hyperplasia A benign form of endometrial hyperplasia with increased number of cells with atypia. The atypical cells are large and irregular and have an increased nuclear/cytoplasmic ratio. The risk of progression to endometrial carcinoma rises with the increasing degree of cell atypia.	5.44	5	3
Endometrial Hyperplasia Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.	10.44	5	3
Insulin Sensitivity [description not available]	2.1	1	0
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.1	1	0
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	7.1	1	0
Animal Mammary Carcinoma [description not available]	3.15	5	0
Innate Inflammatory Response [description not available]	2.11	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.11	1	0
Adenofibroma A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)	3.04	1	0
Complications, Labor [description not available]	3.89	2	1
Fibroadenoma An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)	7.72	3	0
Cat Diseases Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.	3.13	5	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.05	1	0
Abortion, Incomplete Premature loss of PREGNANCY in which not all the products of CONCEPTION have been expelled.	2.06	1	0
Rodent Diseases Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).	2.07	1	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	7.41	2	0
Pus [description not available]	3.4	1	1
Vaginal Discharge A common gynecologic disorder characterized by an abnormal, nonbloody discharge from the genital tract.	3.4	1	1
Cyst [description not available]	2.01	1	0
Bovine Diseases [description not available]	2.02	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.02	1	0
Fetal Death Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.	7.43	2	0
Blastocyst Disintegration [description not available]	2.03	1	0
Inappropriate GH Secretion Syndrome (Acromegaly) [description not available]	3.41	1	1
Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)	3.41	1	1
Endomyometritis Inflammation of both the ENDOMETRIUM and the MYOMETRIUM, usually caused by infections after a CESAREAN SECTION.	3.41	1	1
Endometrial Diseases [description not available]	3.41	1	1
Endometritis Inflammation of the ENDOMETRIUM, usually caused by intrauterine infections. Endometritis is the most common cause of postpartum fever.	3.41	1	1
Uterine Diseases Pathological processes involving any part of the UTERUS.	3.41	1	1
Fibromatosis [description not available]	2.04	1	0
Fibroma A benign tumor of fibrous or fully developed connective tissue.	7.04	1	0

aglepristone

Description

Cross-References

Synonyms (20)

Research Excerpts

Overview

Treatment

Compound-Compound Interactions

Drug Classes (1)

Research

Studies (82)

Market Indicators

Research Demand Index: 58.20

Study Types

aglepristone

Description

Cross-References

Synonyms (20)

Research Excerpts

Overview

Treatment

Compound-Compound Interactions

Drug Classes (1)

Research

Studies (82)

Market Indicators

Research Demand Index: 58.20

Study Types

Related Drugs (21)

Related Conditions (46)